PWPeng Wang

Peng Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peng Wang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Fengshi Li

    Department of Vascular Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    3 shared publications
  • Leng Ni

    Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    3 shared publications
  • Wenzhuo Lian

    Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    3 shared publications
  • Xiao Di

    Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    3 shared publications
  • Zhihua Rong

    Department of Vascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

    3 shared publications
  • ChangWei Liu

    Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

    2 shared publications

Latest Publications

  • Association Between Intramuscular Injection Site and Ulcer Healing in Patients with Chronic Limb-Threatening Ischemia Treated with Recombinant Human Hepatocyte Growth Factor Naked Plasmid: A Post Hoc Analysis of the HOPE CLTI-2 Trial

    by Peng Wang, Wenzhuo Lian, Zhihua Rong, Fengshi Li, Jincan Liu, Junxiu Zhou, Changwei Liu, Xiao Di, Leng Ni

    This study was based on the multicenter, double-blind, randomized phase III HOPE CLTI-2 trial. An exploratory post hoc analysis was performed to investigate the association between intramuscular injection site and ulcer healing outcomes in patients with chronic limb-threatening ischemia (CLTI) treated with recombinant human hepatocyte growth factor (rh-HGF), and to explore factors associated with ulcer healing. The analysis included 108 patients with CLTI treated with rh-HGF, comprising 184 ischemic lower-limb ulcers. Patients were classified according to injection site into a single-segment group, with injections limited to the calf muscles, and a multi-segment group, with injections administered to both the thigh and calf muscles. Outcomes included ulcer healing rate, time to ulcer healing, ankle-brachial index (ABI), Rutherford category, Wound, Ischemia, and foot Infection (WIfI) classification, and adverse clinical events. At the study endpoint, the unadjusted ulcer healing rate was significantly higher in the single-segment group than in the multi-segment group (75.0% vs. 57.1%, p = 0.014), and the observed time to ulcer healing was shorter (153.00 [91.00–184.00] days vs. 181.00 [94.00–191.00] days, p = 0.022). No significant between-group differences were observed in changes in ABI ( p = 0.290) or in WIfI classification ( p = 0.407). However, the distribution of Rutherford categories at study endpoint favored the single-segment group ( p = 0.016). In the multivariable logistic regression analysis, baseline ulcer area (odds ratio [OR]: 0.684, 95% confidence interval [CI]: 0.519–0.901, p = 0.007) and male sex (OR: 3.924, 95% CI: 1.164–13.232, p = 0.028) were independently associated with ulcer healing. Although the unadjusted comparisons favored the single-segment group, injection site was not independently associated with ulcer healing after multivariable adjustment (OR: 1.560, 95% CI: 0.703–3.460, p = 0.269). Therefore, these findings should be considered hypothesis-generating. Whether a more anatomically targeted rh-HGF injection strategy under a fixed-dose regimen can improve ulcer healing requires evaluation in prospectively designed studies.

  • Advancements in Gene-Based Therapeutic Angiogenesis for Chronic Limb-Threatening Ischemia

    by Peng Wang, Xiao Di, Fengshi Li, Zhihua Rong, Wenzhuo Lian, Guoqiang Sun, ChangWei Liu, Leng Ni

    The objective of this article is to summarize the research progress and discuss the current difficulties of gene-based therapeutic angiogenesis in lower limb ischemic diseases, so as to provide new research directions for the non-invasive treatment of lower limb ischemia. The basic and clinical trials of gene-based therapeutic angiogenesis in lower limb ischemia in recent years were read and reviewed. Growth factors such as vascular endothelial growth factor, hepatocyte growth factor, and fibroblast growth factor have been extensively studied for their application in lower limb ischemic diseases. However, clinical studies across various phases have shown inconsistent efficacy endpoints. The efficacy of gene therapy remains questionable. Before exploring efficient methods of delivering pro-angiogenic genes to ischemic tissues, clarification is needed regarding whether the goal of gene therapy is to simply promote collateral circulation or create a conducive tissue microenvironment for angiogenesis. In conclusion, pre-clinical and clinical studies have demonstrated the potential of therapeutic angiogenesis, but more systematic and comprehensive research is needed to explore safer, more effective, and cost-effective treatment methods.


  • Open Access

    Platelet Membrane-Coated HGF-PLGA Nanoparticles Promote Therapeutic Angiogenesis and Tissue Perfusion Recovery in Ischemic Hindlimbs

    by Peng Wang, Xiao Di, Fengshi Li, Zhihua Rong, Wenzhuo Lian, Zongshu Li, Tianqi Chen, Wenjing Wang, Qing Zhong, Guoqiang Sun, et al.

    Therapeutic angiogenesis has garnered significant attention as a potential treatment strategy for lower limb ischemic diseases. Although hepatocyte growth factor (HGF) has been identified as a key promoter of therapeutic angiogenesis, its clinical application is limited due to its short half-life. In this study, we successfully developed and characterized platelet membrane-coated HGF-poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs). These nanoparticles demonstrated enhanced capabilities to promote endothelial cell (EC) proliferation, migration, and tube formation in vitro. Additionally, their efficacy in improving tissue perfusion and promoting angiogenesis was confirmed in a hindlimb ischemia rat model. Our findings suggest that platelet membrane-coated HGF-PLGA-NPs could serve as a promising therapeutic approach for enhancing angiogenesis and restoring tissue perfusion in ischemic conditions.


  • Open Access

    Targeted Knockdown of Hepatic Δ-5 Fatty Acid Desaturase FADS1 Aggravates Atherosclerosis in ApoE-/- Mice

    by Qiulei Liu, Peng Wang, Zhao Yang, Yue Dai, Sheng Wang

    Background: The endogenous metabolism of polyunsaturated fatty acids is regulated by the fatty acid desaturase (FADS) gene cluster and is strongly associated with diseases such as atherosclerosis, dyslipidemia, and type 2 diabetes. However, the association between FADS and atherosclerosis remains a subject of debate. Methods: In this study, we specifically investigated the physiological role of Δ-5 fatty acid desaturase (FADS1) in aortic and peripheral vessel (namely, the femoral artery) atherosclerosis by targeting the selective knockdown of hepatic Fads1 in apolipoprotein E-null (ApoE-⁣/-) mice with antisense oligonucleotides (ASOs). Results: Knockdown of hepatic Fads1 in ApoE-⁣/- mice exacerbated aortic atherosclerosis and non-alcoholic fatty liver disease (NAFLD), resulting in weight loss. Upregulation of FADS1 mRNA expression in more severe atherosclerosis vascular tissues potentially caused the upregulation of angiopoietin-like 4 expression. Conclusions: Our study demonstrated that knockdown of hepatic Fads1 in ApoE-⁣/- mice aggravates spontaneous atherosclerosis and NAFLD but does not affect peripheral atherosclerosis (femoral artery) induced by vascular cuff combined with tandem stenosis.


  • Open Access

    In vitro evaluation of nanoparticle drug-coated balloons: a pectin-RGDS-OC8H17-paclitaxel solution

    by Peng Wang, Lin Gui, Yuji Wang, Sheng Wang

    Drug-coated balloons have proved to be an effective technology in percutaneous transluminal angioplasty in treating peripheral artery disease. Paclitaxel-based coating is mainly used. Solutions to such problems as drug loss and inefficient drug release during operations, however, have not been found yet. This study aims to explore the activity of a newly designed paclitaxel-coated balloon in vitro using pectin as the excipient (pectin-paclitaxel) compared with the commercially available shellac excipient balloon, and to characterize the novel nanoparticle paclitaxel-coated balloon with peptide (Arg-Gly-Asp-Ser, RGDS) derivative RGDS-OC8H17 (pectin-RGDS-OC8H17-paclitaxel). Two coating solutions, pectin-paclitaxel and pectin-RGDS-OC8H17-paclitaxel, were successively designed and prepared. The morphology of both coating solutions was first characterized compared with the control group, the commercially available paclitaxel-coated balloon. Then the in vitro experiments were conducted to determine the drug-releasing profiles of both pectin-paclitaxel and pectin-RGDS-OC8H17-paclitaxel coatings. The pectin-RGDS-OC8H17-paclitaxel-coated balloon was smoother and more homogeneous compared with the commercially available paclitaxel-coated balloon and the pectin-paclitaxel-coated balloon. This difference was more obvious when paclitaxel was at low concentration. During the in vitro trial, the drug-releasing curve of the pectin-RGDS-OC8H17-paclitaxel model showed an adjustable paclitaxel-releasing: more than 90% of the paclitaxel released in 2 h at 300 rpm and more than 99% released in 10 min at 1200 rpm. Compared to the performance of the current commercially available shellac excipient products and the pectin-paclitaxel coating, pectin-RGDS-OC8H17-paclitaxel coating provided higher drug-releasing speed. However, the clinical outcomes of this finding need to be further demonstrated. Paclitaxel-coated balloons as an effective therapeutic strategy currently in treating peripheral arterial disease need to be further improved in terms of its efficiency in anti-proliferative drug delivery and release. The pectin-RGDS-OC8H17-paclitaxel coating solution developed in this study exhibited excellent drug-releasing properties. Further experiments are still needed to demonstrate the performance of this novel drug-coated balloon in vivo and its clinical importance.


  • Open Access

    Wireless bladder pressure monitor for closed-loop bladder neuromodulation

    by Steve Majerus, Anisha S. Basu, Iryna Makovey, Peng Wang, Hui Zhui, Christian Zorman, Wen Ko, Margot S. Damaser

    Conditional neuromodulation is a form of closed-loop bladder control where neurostimulation is applied in reaction to bladder pressure changes. Current methods based on external catheters have limited utility for chronic ambulatory therapy. We have developed a wireless pressure monitor to provide real-time, catheter-free detection of bladder contractions. The device is sized for chronic implantation in the bladder muscle. The pressure monitor consists of an ultra-low-power application specific integrated circuit (ASIC), micro-electro-mechanical (MEMS) pressure sensor, RF antennas, and rechargeable battery. Here we describe an overview of the system, including chronic in vivo test data of a non-hermetic polymer sensor package and chronic testing of the wireless sensor in large animal models. Test results show that the packaging method is viable for chronic encapsulation of implanted pressure sensors. Chronic testing of the pressure monitor revealed some obstacles relating to the chosen implant site within the bladder wall. However, chronic wireless device function was confirmed and data quality was sufficient to detect bladder compressions in large animals, with average correlation coefficient of 0.90.